No Longer Business as Usual: Critical Changes in Investment and IP Strategy for Life Sciences
For life sciences companies rapid changes in healthcare delivery are requiring and inspiring new ways of bringing treatment to patients. Recent actions by the Supreme Court related to Myriad, as well as by the USPTO in the America Invents Act also have had a significant impact on IP and business models within the industry. Financial investors are also taking into consideration these landmark outcomes and adjusting their financing models.
Is Your Life Sciences Company Ready to Address New IP, Regulatory, and Investment Models?
Join Foley & Lardner LLP and QB3 for No Longer Business as Usual: Critical Changes in Investment and IP. During this full-day conference, financial advisors, industry executives and thought-leaders, and legal counsel will present four interactive panels and provide insight on critical business, regulatory, and legal issues to help you address the critical changes occurring as a result of landmark changes happening within the industry.
This event is open to guests of Foley & Lardner LLP, C-level executives, IP counsel and general counsel in life sciences, financial advisors and investors, and life sciences entrepreneurs. For further registration information please contact Meg Ryan (email@example.com).
Please visit http://bit.ly/1987ELv for more information and the full agenda.
When & Where
Foley & Lardner LLP
For more than 25 years, Foley's Life Sciences Team has provided legal services for life sciences enterprises. The cornerstone of our success is our unique ability to blend technical and legal insights with an understanding of our clients' real-world business needs. Our cross-disciplinary team melds legal service in the areas of business, IP, health care, and FDA regulatory law. With special focus in personalized medicine, pharmaceutical and biotech patenting, FDA regulatory, compliance and enforcement, and licensing all operating within a global scope, Foley offers clients a 360—degree approach to their life science technologies.